Drug Profile
Research programme: monoclonal antibody therapeutics - Teva Pharmaceuticals/AbCellera
Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator Teva Pharmaceutical Industries
- Developer Abcellera; Teva Pharmaceutical Industries
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Unspecified in Israel (Parenteral)
- 02 Feb 2016 Early research in Undefined indication in Israel (Parenteral)